Abraxis BioScience Inc. said Wednesday that it has completed the acquisition of the Cruce Davila manufacturing facility in Barceloneta, Puerto Rico formerly owned by Pfizer Inc.

The 56-acre site with a 172,000 square foot manufacturing plant has the capacity to produce injectable pharmaceuticals that meet European Union and U.S. Food and Drug Administration. standards. The facility can also make protein-based biologics and metered dosed inhalers.

The factory includes a 90,000 square foot active pharmaceutical ingredients manufacturing plant and two support structures with quality assurance facilities and laboratories.

Under the terms of the agreement, the Los Angeles-based biotech company will lease the active pharmaceuticals ingredients plant back to Pfizer. Abraxis expects to begin commercial manufacturing from the site before summer.

Shares in Abraxis closed up 5 cents to $25.10.